Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
about
The impact of diabetes on the pathogenesis of sepsisAnti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaB-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus.High-fat diet induces Ikkbeta and reduces insulin sensitivity in rats with low running capacity.Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosisAdipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes.Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Lipid-induced insulin resistance is prevented in lean and obese myotubes by AICAR treatment.Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKbeta Action in a Fiber-Type Specific Manner.An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol.Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetesAdipose inflammation: cause or consequence of obesity-related insulin resistanceChronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype?Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticalsDownregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery diseaseSerum levels of monocyte chemoattractant protein-1 and all-cause and cardiovascular mortality among patients with coronary artery disease.Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers.Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetesIs there an estrogenic component in the metabolic syndrome?Human adipose dynamics and metabolic healthEffect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectivesLipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats.Identification of sucrose non-fermenting-related kinase (SNRK) as a suppressor of adipocyte inflammationObesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways.Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study.Mechanism for improved insulin sensitivity after gastric bypass surgeryFoxO1 links insulin resistance to proinflammatory cytokine IL-1beta production in macrophages.Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice.Ginseng oligopeptides protect against irradiation-induced immune dysfunction and intestinal injury
P2860
Q24616935-7E07E599-A62F-4A4E-BD27-9FDCA879DC8DQ33412579-02BC4034-4C2E-4212-AC3E-19F8FBF136FCQ33738196-668F9621-3705-466C-8E34-7958805D614CQ33750679-5F87E3AD-A9B0-44A7-AD75-FC76504A600DQ33862296-1DFC851C-9D68-44CC-B625-CD9C8CCC1120Q33880303-8461F020-CD2F-4C3E-A2F6-3C71CBEB6F45Q33917490-BC258622-9445-446E-99F0-3CB564EC4C1CQ34078722-5B4E9AAB-2BC0-471D-9EF5-2F6846082336Q34113077-E981BCCE-F25D-4FF1-BCDF-F4A42C96076FQ34509903-915E11F6-A724-4C9E-A3E6-AA35E3C47C23Q34642513-CCBDE82D-082E-4EB1-9C2A-150C2F136AC2Q34684222-826138D5-900D-407E-A724-E8014B0AB546Q35129349-765872DA-26B1-4A9C-AF5B-D16E5443B8FCQ35130917-9C6D2137-AF24-47CE-8A63-18804274F718Q35192639-4CEAC5F6-BDD5-4205-A21D-96ABBA7A7E58Q35827821-6D458F42-9A50-49DE-8F41-38EE932BB270Q36222092-47B8C799-58BF-480F-AAA3-663A54AC2B8FQ36267934-07CCE8F0-F256-4856-8631-850860AA894BQ36745558-DDC42BF6-413B-4489-919B-CCFDA4069AC5Q36805400-DAF51EC0-8D84-4A14-8ABC-CE6168ACF3E6Q36812788-0C892415-5456-4C99-8A5A-E694A1EB99D7Q36841315-092A882F-3F16-4156-B7D0-0449E7765072Q37014875-82854E26-1D41-4279-A77E-C472788204BAQ37022992-C6161960-0D3B-4E21-AD68-78B07BF74FD3Q37143485-3F530F6C-BD16-450C-99EF-2E352F35494CQ37206752-DB13B145-124D-428D-8920-0DE6A12D600FQ37311381-F8D3D891-B141-4F39-8C40-F968BAD64B74Q37400789-F7C38E1E-E1A0-435F-A9C2-B84D9DD806D8Q37583596-78947AC6-B740-4F97-A997-3983B87EDFADQ41854974-65775A3A-FC90-4CC2-AFBB-F51F99A46B85Q58733872-EDA09E78-AD0F-43D9-8809-FCA52A0819E8
P2860
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@ast
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@en
type
label
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@ast
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@en
prefLabel
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@ast
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@en
P2093
P356
P1476
Suppression of nuclear factor- ...... sclerotic effect in the obese.
@en
P2093
Kumbkarni Y
P304
P356
10.1210/JCEM.86.3.7309
P407
P577
2001-03-01T00:00:00Z